BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lakefront Biotherapeutics NV readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Lakefront Biotherapeutics NV's dr
 ugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05299424-3157@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gamgertamig (CM336): Phase 1/2 readout est. (NCT05299424)
DESCRIPTION:Gamgertamig (CM336)\, phase 1/2\, Multiple Myeloma.\nStudy: A S
 tudy of CM336 in Patients With Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05299424
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181239-3157@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Gamgertamig (CM336): Phase 3 readout est. (NCT07181239)
DESCRIPTION:Gamgertamig (CM336)\, phase 3\, Multiple Myeloma.\nStudy: Study
  of CM336 in Relapsed or Refractory Multiple Myeloma Patients\nEstimated p
 rimary completion: September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07181239
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175493-3157@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20271118
DTEND;VALUE=DATE:20271119
SUMMARY:Gamgertamig (CM336): Phase 1/2 readout est. (NCT07175493)
DESCRIPTION:Gamgertamig (CM336)\, phase 1/2.\nStudy: A Study of CM336 in Pa
 tients With Relapsed or Refractory Autoimmune Cytopenia\nEstimated primary
  completion: 18 November 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07175493
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07910903-3157@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Gamgertamig (CM336): Phase 3 readout est. (NCT07910903)
DESCRIPTION:Gamgertamig (CM336)\, phase 3\, Multiple Myeloma.\nStudy: Study
  of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractor
 y Multiple Myeloma\nEstimated primary completion: May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07910903
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
